Your browser is no longer supported. Please, upgrade your browser.
ARNA Arena Pharmaceuticals, Inc. monthly Stock Chart
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.43 Insider Own0.59% Shs Outstand242.88M Perf Week1.20%
Market Cap408.03M Forward P/E- EPS next Y-0.31 Insider Trans-1.29% Shs Float241.85M Perf Month-9.19%
Income-105.20M PEG- EPS next Q-0.10 Inst Own53.10% Short Float5.36% Perf Quarter-9.19%
Sales35.90M P/S11.37 EPS this Y-62.90% Inst Trans-0.06% Short Ratio7.24 Perf Half Y-1.18%
Book/sh0.15 P/B11.20 EPS next Y8.80% ROA-37.80% Target Price3.00 Perf Year-59.52%
Cash/sh- P/C- EPS next 5Y- ROE-150.00% 52W Range1.30 - 4.31 Perf YTD-11.58%
Dividend- P/FCF- EPS past 5Y17.00% ROI-84.70% 52W High-61.02% Beta-0.56
Dividend %- Quick Ratio3.00 Sales past 5Y18.20% Gross Margin63.30% 52W Low29.23% ATR0.10
Employees228 Current Ratio3.20 Sales Q/Q-20.30% Oper. Margin- RSI (14)48.48 Volatility5.45% 5.35%
OptionableYes Debt/Eq1.80 EPS Q/Q13.90% Profit Margin- Rel Volume1.90 Prev Close1.78
ShortableYes LT Debt/Eq1.72 EarningsAug 03 AMC Payout- Avg Volume1.79M Price1.68
Recom2.70 SMA20-0.77% SMA50-3.64% SMA200-6.69% Volume3,395,667 Change-5.62%
Mar-01-16Reiterated RBC Capital Mkts Sector Perform $2 → $1.50
Nov-11-15Reiterated RBC Capital Mkts Sector Perform $5 → $2
Oct-28-15Reiterated WallachBeth Buy $6 → $4
May-12-15Reiterated WallachBeth Buy $8 → $6
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Sep-20-10Reiterated UBS Neutral $7 → $2
Sep-17-10Downgrade Davenport Buy → Neutral
Sep-14-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
Aug-23-10Reiterated UBS Neutral $3.50 → $7
Jul-16-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
Jul-02-10Reiterated UBS Buy $40 → $38
Feb-04-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
Dec-17-09Initiated Jefferies & Co Hold $4
Sep-21-09Downgrade Leerink Swann Outperform → Mkt Perform $6
Sep-18-09Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $3
Sep-15-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Jul-21-16 08:17AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : July 21, 2016
Jul-20-16 10:10AM  Company News for July 20, 2016
Jul-19-16 12:43PM  Arena Pharmaceuticals (ARNA) Stock Gains as FDA Approves Weight-Loss Drug
10:20AM  Eisai And Arena Pharmaceuticals Get FDA Approval For BELVIQ XR Extended-Release Tablets
09:02AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
08:40AM  Arena Pharma stock rises 8.8% after weight-loss drug is approved at MarketWatch
08:26AM  Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets PR Newswire
Jul-14-16 11:51AM  Eisai, Arena Pharmaceuticals Get Regulatory Approval For VENESPRI In Mexico
08:21AM  Arena Pharmaceuticals stock soars after weight drug approved in Mexico at MarketWatch
08:05AM  Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI® (lorcaserin HCl) in Mexico PR Newswire
Jul-05-16 11:38AM  Arena Pharmaceuticals to Slash Workforce By 73% (ARNA) at Investopedia
Jul-01-16 09:37AM  Arena (ARNA) to Cut 73% Workforce, Shifts Focus to Pipeline
Jun-30-16 04:21PM  Arena Pharma to lay off 73% of workforce; shares halted at MarketWatch
04:17PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities
04:05PM  Arena Pharmaceuticals Announces Shift to Focus on Proprietary Clinical Stage Pipeline PR Newswire
Jun-28-16 09:31AM  These Biotech Companies Are Prime For a Breakout as the Market for Smoking Cessation Products Heats Up
08:12AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : June 28, 2016
Jun-21-16 09:00AM  Buy Insys Therapeutics Before Medical Marijuana Reaches A Tipping Point at Forbes
Jun-16-16 06:07AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
Jun-15-16 11:57AM  Arena Pharmaceuticals Hires Kevin Lind As CFO
11:16AM  Heres Why Traders Are Buzzing about These Five Stocks at Insider Monkey
07:00AM  Arena Pharmaceuticals Announces Appointment of Kevin R. Lind as Chief Financial Officer PR Newswire
Jun-13-16 04:41PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure
07:00AM  Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334 PR Newswire
Jun-09-16 08:58AM  Orexigen Stock Gains More than 50% on Markman Hearing
Jun-06-16 07:02AM  Antidote Company's Valuation Misaligned With Growing Crisis +7.49%
Jun-01-16 10:51AM  Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
10:21AM  The Little-Known Reason Arena Pharmaceuticals Could Be a Winner at Motley Fool
08:27AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : June 1, 2016
May-28-16 03:11PM  How Hedge Funds Traded Marijuana Stocks in Q1 at Insider Monkey
May-26-16 07:10PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : May 26, 2016
May-23-16 01:05PM  Drawing Biopharma Concepts With A Crayon at Motley Fool
May-18-16 01:04PM  ARENA PHARMACEUTICALS INC Financials
May-16-16 06:40PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : May 16, 2016
May-13-16 10:21AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q1, 2016 By the Numbers
May-10-16 08:27AM  Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
07:30AM  Boston drug firm's shares slump due to job cuts, cash shortage at American City Business Journals
12:57AM  Edited Transcript of ARNA earnings conference call or presentation 9-May-16 9:00pm GMT
May-09-16 05:14PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
05:07PM  Arena Pharmaceuticals reports 1Q loss
04:05PM  Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
04:05PM  Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer PR Newswire
07:07AM  Q1 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close CCBN
May-06-16 03:42PM  Arena Pharmaceuticals' Shares Slid 13% in April: Can the Stock Bounce Back? at Motley Fool
09:43AM  Drug Stocks Reporting Early Next Week: TEVA, ARNA & More Zacks
May-04-16 08:07AM  Arena (ARNA) Q1 Earnings: What's in Store for the Stock? Zacks
May-02-16 04:05PM  Arena Pharmaceuticals to Host First Quarter 2016 Financial Results and Corporate Update Conference Call and Webcast on Monday, May 9 PR Newswire
08:53AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : May 2, 2016 at Capital Cube
Apr-21-16 07:46AM  New Strong Sell Stocks for April 21st Zacks
Apr-17-16 10:04AM  How Much Potential Does Saxenda Hold for Novo?
Apr-13-16 01:00PM  Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study
09:52AM  New Strong Sell Stocks for April 13th
Apr-12-16 01:33PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
01:21PM  Arena Pharma (ARNA) Stock Advancing on Favorable Trial Results at TheStreet
08:00AM  Arena Pharmaceuticals Reports Favorable Results from Phase 1b Multiple-Ascending Dose Clinical Trial of APD371 PR Newswire
Apr-08-16 05:25PM  Arena Pharmaceuticals, Inc. Rides Celgene's Coattails to Big Gains in March at Motley Fool -5.00%
Mar-28-16 08:33AM  Arena Pharmaceuticals Extends Its Winning Streak (ARNA, CELG) at Investopedia
08:02AM  Analyst Report; Expected FDA Decisions Around the Corner Accesswire
Mar-22-16 11:31AM  Stocks to Watch for Tuesday 3/22/2016, If You Choose Accesswire +8.99%
Mar-21-16 01:35PM  Why Arena Pharmaceuticals Surged 10% Last Week (ARNA) at Investopedia +7.88%
08:15AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : March 21, 2016
06:07AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure
Mar-16-16 12:19PM  Hedge Funds Think These 4 Marijuana Stocks Are Pretty Dope at Insider Monkey
Mar-15-16 10:15AM  Why Investors Should Sell These Biotech Stocks & Buy Gilead Instead -5.88%
Mar-14-16 05:45PM  How Speculation Drives Investment in Arena Pharmaceuticals (ARNA) at Investopedia
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Amgen, Regeneron Pharmaceuticals and Arena Pharmaceuticals
Mar-11-16 09:37AM  Biotech Investing Guide: 3 Stocks to Buy and 3 to Avoid
Mar-08-16 09:56AM  New Strong Sell Stocks for March 8th -5.66%
06:36AM  Analyzing Arena Pharma's Return on Equity (ARNA, IMGN) at Investopedia
Mar-04-16 09:13AM  New Strong Sell Stocks for March 4th
Mar-01-16 09:30AM  Arena's (ARNA) Q4 Loss Narrower but Revenues Fall Short
Feb-29-16 11:50PM  Edited Transcript of ARNA earnings conference call or presentation 29-Feb-16 10:00pm GMT
05:21PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:33PM  Arena Pharmaceuticals reports 4Q loss
04:19PM  Arena Pharmaceuticals (ARNA) Stock Edges Lower in After-Hours Trading on Q4 Results at TheStreet
04:00PM  Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update PR Newswire
07:07AM  Q4 2015 Arena Pharmaceuticals Inc Earnings Release - After Market Close
Feb-26-16 01:20PM  Will Arena (ARNA) Post a Narrower-than-Expected 4Q Loss?
Feb-23-16 08:00AM  Arena Pharmaceuticals to Host Fourth Quarter and Full Year 2015 Financial Results and Corporate Update Conference Call and Webcast on Monday, February 29 PR Newswire -9.88%
Feb-16-16 09:00AM  Small Cap Acquisition Candidates See Increased Investor Interest Accesswire
Feb-09-16 10:23AM  Here's Why Arena Pharmaceuticals Lost 17% of Its Value in January at Motley Fool
Feb-08-16 08:00AM  Biotechnology Stocks Technical Review -- MannKind, Array BioPharma, Arena Pharma, and Chimerix Accesswire
Jan-20-16 03:33PM  Former US president Jimmy Carter Says His Brain Cancer Has Disappeared Accesswire +7.74%
Jan-19-16 10:17AM  Bioelectronic-Medicine Leader Endonovo Therapeutics, Inc. Begins 2016 on a Strong Note Accesswire -6.06%
Jan-13-16 04:25PM  Arena, Boehringer Ingelheim Ink Deal, Schizophrenia in Focus
Jan-12-16 05:19PM  [$$] Arena Pharma Shares Rise on Collaboration Pact With Boehringer at The Wall Street Journal +8.28%
04:55PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
04:05PM  Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia PR Newswire
Jan-07-16 01:02PM  This Company is Up +400% in a Month Accesswire -6.86%
12:04PM  Arena Pharmaceuticals Ends 2015 On a Sour Note: Can It Recover in 2016? at Motley Fool
08:15AM  CEL-SCI Corp (CVM) Shows Strength: Stock Moves Up 8.3%
08:00AM  Arena Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-06-16 08:00AM  Biotechnology Equity Picks - Arena Pharma, uniQure, Cytokinetics, and Curis Accesswire -5.91%
Jan-05-16 05:05PM  Teva/Active Biotech Halt High Doses of Laquinimod for MS
01:50PM  Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Jan-04-16 08:05AM  Pluristem Therapeutics (PSTI) in Focus: Stock Rises 14.1%
Dec-30-15 10:23AM  The Worst 3 Biotech Stocks for 2016 at Motley Fool
08:02AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : December 30, 2015
Dec-29-15 09:30AM  New Strong Buy Stocks for December 29th
Dec-23-15 08:00AM  Biotechnology Equities Update -- Arena Pharma, Compugen, ChemoCentryx, and Concert Pharma Accesswire
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the United States and South Korea. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include APD334, a modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which is in Phase II clinical trials; and Ralinepag that is in Phase II clinical trials for the treatment of pulmonary arterial hypertension. The company's products under development also comprise APD371, an agonist of the cannabinoid-2 receptor that is in Phase I clinical trials for the treatment of pain; Nelotanserin, which is in Phase II clinical trials for the treatment of dementia-associated psychosis; Temanogrel, which is in Phase I clinical trials for thrombotic diseases; and Undisclosed Orphan GPCR that is in pre-clinical development for central nervous system indications. In addition, it manufactures drug products under a toll manufacturing agreement for Siegfried AG. Arena Pharmaceuticals, Inc. has collaboration with Boehringer Ingelheim International GmbH. The company was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
White Christine AnnaDirectorJun 13Sale1.9918,72837,29985,529Jun 15 08:55 PM